ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

  • Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen for treating type 2 diabetes mellitus:

    • as a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and
    • in combination with insulin and metformin, unless metformin is contraindicated or not tolerated.

Funding status

Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 February 2023.

MAF assistance does not apply to any formulations or strengths of liraglutide or semaglutide for treating type 2 diabetes mellitus.


GLP-1 receptor agonist injections for treating type 2 diabetes mellitus (19 December 2022) PES Non-insulin injectable drugs for treating type 2 diabetes mellitus (19 December 2022)